China’s CAR-T Cell Therapy: Leading a New Revolution in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma (MCL)

MCL

#CARTCellTherapy #MantleCellLymphoma #RelapsedMCL #RefractoryMCL #Hematology #MCL

Mantle Cell Lymphoma (MCL), a rare and complex subtype of non-Hodgkin’s lymphoma, exhibits both aggressive and indolent characteristics. Since MCL patients are usually diagnosed at an advanced stage, often with poor prognostic factors, traditional treatments such as chemotherapy and immunotherapy have brought survival benefits to some patients. However, most still face disease relapse or progression, particularly those with relapsed/refractory (r/r) MCL, where treatment poses significant challenges. For a long time, treatment options for MCL have been limited, making it difficult to achieve long-term remission or cure, highlighting the need for breakthroughs.

Chinese CAR-T Cell Therapy: Offering Hope for Relapsed/Refractory MCL With the rapid development of biotherapeutics, Chinese CAR-T cell therapy has emerged as a breakthrough innovation in lymphoma treatment. Since the approval of the world’s first CAR-T product in 2017, China has made significant progress in CAR-T research and application, especially in treating r/r MCL, where CAR-T therapy has shown excellent efficacy. CAR-T therapy not only significantly improves patient remission rates but also offers new survival opportunities for high-risk patients with poor prognoses.

Efficacy: In recent years, multiple international and Chinese clinical studies have confirmed the efficacy of CAR-T cell therapy in patients with relapsed/refractory MCL. Clinical data from China have also demonstrated outstanding results. In August 2024, the Chinese CAR-T product Relmacabtagene Autoleucel, a CD19-targeted CAR-T cell therapy, was approved for its third indication, treating adult patients with relapsed/refractory MCL (r/r MCL). Clinical data showed that Relmacabtagene Autoleucel achieved an overall response rate of 81.4%, with a complete response rate of 67.8%. The median progression-free survival (PFS) was 13 months, and the median overall survival (OS) was 19.5 months. These data further prove that Chinese CAR-T cell therapy not only has high efficacy in r/r MCL patients but also provides lasting survival benefits.

Side Effect Management: Despite its remarkable efficacy, CAR-T therapy is associated with certain side effects, such as cytokine release syndrome (CRS) and neurotoxicity (NT). However, with the continuous optimization of treatment technologies and accumulated experience in China, the incidence of side effects has been effectively controlled. In treating relapsed/refractory MCL patients, Chinese medical teams have been able to limit the occurrence of grade ≥3 CRS and NT to 6.8% in clinical practice. This lower toxicity makes CAR-T therapy safer in clinical applications, offering a new option for patients who cannot tolerate traditional treatments. Particularly for those who are resistant to Bruton’s tyrosine kinase inhibitors (BTKi) or ineligible for autologous hematopoietic stem cell transplantation, Chinese CAR-T therapy provides a gentler and effective treatment option.

Indications: The following groups of patients can benefit from Chinese CAR-T cell therapy:

1. Patients with relapsed/refractory MCL (r/r MCL)

2. MCL patients who do not respond to conventional treatments

3. Patients with poor prognostic factors (TP53 mutation, Ki67≥30%, blastoid MCL, pleomorphic MCL, POD24)

4. Patients previously exposed to BTKi or resistant/relapsed/refractory MCL

5. High-risk patients unsuitable for transplantation who cannot achieve good remission

Conclusion: With the widespread application of Chinese CAR-T therapy globally, more MCL patients, both domestic and international, are able to achieve deep remission and long-term survival. This not only marks a significant advancement in China’s hematological cancer treatment but also signifies that Chinese CAR-T cell therapy is leading a new transformation in the treatment of relapsed/refractory lymphoma worldwide.

🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070 

Email: doctor.huang@globecancer.com

#CancerTreatment  #Immunotherapy #CancerResearch #Chinesemedicalbreakthrough #LymphomaTreatment #Oncology #Biotherapy #CancerInnovation

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

3 months ago Lymphoma

CAR-T Therapy in China: Relma-cel Offers Deep and Lasting Remission for Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)

CAR-T Therapy in China: Relma-cel Offers Deep and Lasting Remission for Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)

MCL

#MantleCellLymphoma #MCL  #Lymphoma #RRMCL  #RelmaCel #CART #Non-HodgkinLymphoma #NHL

In the global cancer treatment landscape, the advancements in CAR-T cell therapy are remarkable, particularly in the treatment of relapsed and refractory Mantle Cell Lymphoma (MCL). China’s CAR-T therapy, Relma-cel, has emerged as a new beacon of hope for patients, delivering deep and lasting remission for those who have undergone multiple lines of treatment.

Mantle Cell Lymphoma: A Complex and Challenging Disease

Mantle Cell Lymphoma (MCL) is a subtype of Non-Hodgkin Lymphoma (NHL) originating from B cells, accounting for 6% to 8% of all NHL cases. The disease typically affects older adults, and most patients are diagnosed at an advanced stage with poor prognostic factors. Despite the availability of various treatments, including Bruton’s Tyrosine Kinase inhibitors (BTKi), MCL remains difficult to cure, and patients often face recurrence or progression of the disease.

Relma-cel: A New Hope for Relapsed/Refractory MCL

In China, Relma-cel, a novel CAR-T cell therapy, was approved by the National Medical Products Administration (NMPA) in August 2024 for the treatment of adult patients with relapsed or refractory MCL who have failed multiple lines of therapy. This therapy offers a groundbreaking treatment option for MCL patients.

A Case Study: Deep Remission Achieved with CAR-T Therapy

A 51-year-old male MCL patient, after multiple treatment failures, eventually achieved complete remission through the CAR-T therapy Relma-cel. Diagnosed in 2014, the patient underwent R-CHOP chemotherapy, Rituximab-targeted therapy, as well as BTKi and PI3K inhibitor treatments. However, the disease continued to relapse with poor prognosis. Finally, in 2022, the patient achieved deep and lasting remission through CAR-T therapy. After CAR-T cell infusion, the patient reached complete remission within just one month and remained in remission for 22 months of follow-up.

Expert Commentary: The Future of CAR-T Therapy

Professor Li Ping from Tongji Hospital, Tongji University, highlighted that CAR-T cell therapy has broken through the limitations of traditional treatments for relapsed/refractory MCL, offering new hope for high-risk patients. For those who cannot benefit from conventional treatments, the introduction of CAR-T therapy is crucial, especially when applied early in the frontline treatment stage to maximize its efficacy.

Based on the latest clinical research data, Relma-cel has shown encouraging complete remission rates (67.8%) and objective response rates (81.36%) in treating relapsed/refractory MCL patients. These findings further underscore the importance of CAR-T cell therapy in patients who have failed BTKi treatment, positioning it as a potential first-choice treatment for these patients.

Globally, CAR-T therapy has become a standard treatment for relapsed/refractory MCL, particularly in third-line treatment settings. For patients with poor prognostic factors, CAR-T therapy may be key to overcoming the limitations of traditional treatments and extending survival.

Conclusion

As CAR-T cell therapy continues to evolve, more patients with relapsed/refractory MCL will have the opportunity to benefit from it. The clinical application of Relma-cel not only brings deep and lasting remission to patients but also sets a new example for the development of CAR-T therapy worldwide. With early intervention and precise treatment strategies, CAR-T therapy has the potential to create a brighter future for MCL patients.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China  for preliminary evaluation!

WhatsApp: +8613717959070

（Https://wa.me/+8613717959070）

Email: doctor.huang@globecancer.com

#CAR_T #CancerTreatment #RelmaCel #MCL #LymphomaAwareness #Oncology #Immunotherapy #MedicalInnovation #CancerResearch #ChinaHealthcare